Back to Search
Start Over
Structural-Guided Identification of Small Molecule Inhibitor of UHRF1 Methyltransferase Activity.
- Source :
-
Frontiers in genetics [Front Genet] 2022 Aug 03; Vol. 13, pp. 928884. Date of Electronic Publication: 2022 Aug 03 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Ubiquitin-like containing plant homeodomain Ring Finger 1 (UHRF1) protein is recognized as a cell-cycle-regulated multidomain protein. UHRF1 importantly manifests the maintenance of DNA methylation mediated by the interaction between its SRA (SET and RING associated) domain and DNA methyltransferase-1 (DNMT1)-like epigenetic modulators. However, overexpression of UHRF1 epigenetically responds to the aberrant global methylation and promotes tumorigenesis. To date, no potential molecular inhibitor has been studied against the SRA domain. Therefore, this study focused on identifying the active natural drug-like candidates against the SRA domain. A comprehensive set of in silico approaches including molecular docking, molecular dynamics (MD) simulation, and toxicity analysis was performed to identify potential candidates. A dataset of 709 natural compounds was screened through molecular docking where chicoric acid and nystose have been found showing higher binding affinities to the SRA domain. The MD simulations also showed the protein ligand interaction stability of and in silico toxicity analysis has also showed chicoric acid as a safe and nontoxic drug. In addition, chicoric acid possessed a longer interaction time and higher LD50 of 5000 mg/kg. Moreover, the global methylation level (%5 mC) has been assessed after chicoric acid treatment was in the colorectal cancer cell line (HCT116) at different doses. The result showed that 7.5 µM chicoric acid treatment reduced methylation levels significantly. Thus, the study found chicoric acid can become a possible epidrug-like inhibitor against the SRA domain of UHRF1 protein.<br />Competing Interests: AA is employed by the Translational Research Institute, Hamad Medical Corporation, Qatar. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Awal, Nur, Al Khalaf, Rehan, Ahmad, Hosawi, Choudhry and Khan.)
Details
- Language :
- English
- ISSN :
- 1664-8021
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Frontiers in genetics
- Publication Type :
- Academic Journal
- Accession number :
- 35991572
- Full Text :
- https://doi.org/10.3389/fgene.2022.928884